Polycystic ovary syndrome

Last updated
Polycystic ovary syndrome
Other namesHyperandrogenic anovulation (HA), [1] Stein-Leventhal syndrome [2]
Polycystic Ovaries.jpg
A polycystic ovary
Specialty Gynecology, endocrinology
Symptoms Irregular menstrual periods, heavy periods, excess hair, acne, pelvic pain, difficulty getting pregnant, patches of thick, darker, velvety skin [3]
Complications Type 2 diabetes, obesity, obstructive sleep apnea, heart disease, mood disorders, endometrial cancer [4]
DurationLong term [5]
CausesGenetic and environmental factors [6] [7]
Risk factors Obesity, not enough exercise, family history [8]
Diagnostic method Based on anovulation, high androgen levels, ovarian cysts [4]
Differential diagnosis Adrenal hyperplasia, hypothyroidism, high blood levels of prolactin [9]
TreatmentWeight loss, exercise [10] [11]
Medication Birth control pills, metformin, anti-androgens [12]
Frequency2% to 20% of women of childbearing age [8] [13]

Polycystic ovary syndrome, or polycystic ovarian syndrome (PCOS), is the most common endocrine disorder in women of reproductive age. [14] The syndrome is named after cysts which form on the ovaries of some people with this condition, though this is not a universal symptom, and not the underlying cause of the disorder. [15] [16]

Contents

People with PCOS may experience irregular menstrual periods, heavy periods, excess hair, acne, pelvic pain, difficulty getting pregnant, and patches of thick, darker, velvety skin. [3] The primary characteristics of this syndrome include: hyperandrogenism, anovulation, insulin resistance, and neuroendocrine disruption. [17]

A review of international evidence found that the prevalence of PCOS could be as high as 26% among some populations, though ranges between 4% and 18% are reported for general populations. [18] [19] [20]

The exact cause of PCOS remains uncertain, and treatment involves management of symptoms using medication. [19]

Definition

Two definitions are commonly used:

In 1990, a consensus workshop sponsored by the NIH/NICHD suggested that a person has PCOS if they have all of the following: [21]
  1. oligoovulation
  2. signs of androgen excess (clinical or biochemical)
  3. exclusion of other disorders that can result in menstrual irregularity and hyperandrogenism (e.g.: Congenital Suprarrenal Hyperplasia, androgen producer tumors, hyperprolactinemia).

In 2003, a consensus workshop sponsored by ESHRE/ASRM in Rotterdam indicated PCOS to be present if any two out of three criteria are met, in the absence of other entities that might cause these findings: [22] [23] [24]

  1. oligoovulation and/or anovulation
  2. excess androgen activity
  3. polycystic ovaries (by gynecologic ultrasound)

The Rotterdam definition is wider, including many more women, the most notable ones being women without androgen excess. Critics say that findings obtained from the study of women with androgen excess cannot necessarily be extrapolated to women without androgen excess. [25] [26]

In 2006, the Androgen Excess PCOS Society suggested a tightening of the diagnostic criteria to all of the following: [22]
  1. excess androgen activity
  2. oligoovulation/anovulation and/or polycystic ovaries
  3. exclusion of other entities that would cause excess androgen activity

Signs and symptoms

Signs and symptoms of PCOS include irregular or no menstrual periods, heavy periods, excess body and facial hair, acne, pelvic pain, difficulty getting pregnant, and patches of thick, darker, velvety skin, [3] ovarian cysts, enlarged ovaries, excess androgen, and weight gain. [27] [28]

Associated conditions include type 2 diabetes, obesity, obstructive sleep apnea, heart disease, mood disorders, and endometrial cancer. [4]

Common signs and symptoms of PCOS include the following:

Women with PCOS tend to have central obesity, but studies are conflicting as to whether visceral and subcutaneous abdominal fat is increased, unchanged, or decreased in women with PCOS relative to non-PCOS women with the same body mass index. [37] In any case, androgens, such as testosterone, androstanolone (dihydrotestosterone), and nandrolone decanoate have been found to increase visceral fat deposition in both female animals and women. [38]

Although 80% of PCOS presents in women with obesity, 20% of women diagnosed with the disease are non-obese or "lean" women. [39] However, obese women that have PCOS have a higher risk of adverse outcomes, such as hypertension, insulin resistance, metabolic syndrome, and endometrial hyperplasia. [40]

Even though most women with PCOS are overweight or obese, it is important to acknowledge that non-overweight women can also be diagnosed with PCOS. Up to 30% of women diagnosed with PCOS maintain a normal weight before and after diagnosis. "Lean" women still face the various symptoms of PCOS with the added challenges of having their symptoms properly addressed and recognized. Lean women often go undiagnosed for years, and usually are diagnosed after struggles to conceive. [41] Lean women are likely to have a missed diagnosis of diabetes and cardiovascular disease. These women also have an increased risk of developing insulin resistance, despite not being overweight. Lean women are often taken less seriously with their diagnosis of PCOS, and also face challenges finding appropriate treatment options. This is because most treatment options are limited to approaches of losing weight and healthy dieting. [42]

Hormone levels

Testosterone levels are usually elevated in women with PCOS. [43] [44] In a 2020 systematic review and meta-analysis of sexual dysfunction related to PCOS which included 5,366 women with PCOS from 21 studies, testosterone levels were analyzed and were found to be 2.34 nmol/L (67 ng/dL) in women with PCOS and 1.57 nmol/L (45 ng/dL) in women without PCOS. [44] In a 1995 study of 1,741 women with PCOS, mean testosterone levels were 2.6 (1.1–4.8) nmol/L (75 (32–140) ng/dL). [45] In a 1998 study which reviewed many studies and subjected them to meta-analysis, testosterone levels in women with PCOS were 62 to 71 ng/dL (2.2–2.5 nmol/L) and testosterone levels in women without PCOS were about 32 ng/dL (1.1 nmol/L). [46] In a 2010 study of 596 women with PCOS which used liquid chromatography–mass spectrometry (LC–MS) to quantify testosterone, median levels of testosterone were 41 and 47 ng/dL (with 25th–75th percentiles of 34–65 ng/dL and 27–58 ng/dL and ranges of 12–184 ng/dL and 1–205 ng/dL) via two different labs. [47] If testosterone levels are above 100 to 200 ng/dL, per different sources, other possible causes of hyperandrogenism, such as congenital adrenal hyperplasia or an androgen-secreting tumor, may be present and should be excluded. [45] [48] [43]

Associated conditions

Warning signs may include a change in appearance. But there are also manifestations of mental health problems, such as anxiety, depression, and eating disorders. [27] [ medical citation needed ]

A diagnosis of PCOS suggests an increased risk of the following:

The risk of ovarian cancer and breast cancer is not significantly increased overall. [49]

Cause

PCOS is a heterogeneous disorder of uncertain cause. [62] [63] There is some evidence that it is a genetic disease. Such evidence includes the familial clustering of cases, greater concordance in monozygotic compared with dizygotic twins and heritability of endocrine and metabolic features of PCOS. [7] [62] [63] There is some evidence that exposure to higher than typical levels of androgens and the anti-Müllerian hormone (AMH) in utero increases the risk of developing PCOS in later life. [64]

It may be caused by a combination of genetic and environmental factors. [6] [7] [65] Risk factors include obesity, a lack of physical exercise, and a family history of someone with the condition. [8] Diagnosis is based on two of the following three findings: anovulation, high androgen levels, and ovarian cysts. [4] Cysts may be detectable by ultrasound. [9] Other conditions that produce similar symptoms include adrenal hyperplasia, hypothyroidism, and high blood levels of prolactin. [9]

Genetics

The genetic component appears to be inherited in an autosomal dominant fashion with high genetic penetrance but variable expressivity in females; this means that each child has a 50% chance of inheriting the predisposing genetic variant(s) from a parent, and, if a daughter receives the variant(s), the daughter will have the disease to some extent. [63] [66] [67] [68] The genetic variant(s) can be inherited from either the father or the mother, and can be passed along to both sons (who may be asymptomatic carriers or may have symptoms such as early baldness and/or excessive hair) and daughters, who will show signs of PCOS. [66] [68] The phenotype appears to manifest itself at least partially via heightened androgen levels secreted by ovarian follicle theca cells from women with the allele. [67] The exact gene affected has not yet been identified. [7] [63] [69] In rare instances, single-gene mutations can give rise to the phenotype of the syndrome. [70] Current understanding of the pathogenesis of the syndrome suggests, however, that it is a complex multigenic disorder. [71]

Due to the scarcity of large-scale screening studies, the prevalence of endometrial abnormalities in PCOS remains unknown, though women with the condition may be at increased risk for endometrial hyperplasia and carcinoma as well as menstrual dysfunction and infertility.

The severity of PCOS symptoms appears to be largely determined by factors such as obesity. [7] [22] [72] PCOS has some aspects of a metabolic disorder, since its symptoms are partly reversible. Even though considered as a gynecological problem, PCOS consists of 28 clinical symptoms. [73]

Even though the name suggests that the ovaries are central to disease pathology, cysts are a symptom instead of the cause of the disease. Some symptoms of PCOS will persist even if both ovaries are removed; the disease can appear even if cysts are absent. Since its first description by Stein and Leventhal in 1935, the criteria of diagnosis, symptoms, and causative factors are subject to debate. Gynecologists often see it as a gynecological problem, with the ovaries being the primary organ affected. However, recent insights show a multisystem disorder, with the primary problem lies in hormonal regulation in the hypothalamus, with the involvement of many organs. The term PCOS is used due to the fact that there is a wide spectrum of symptoms possible. It is common to have polycystic ovaries without having PCOS; approximately 20% of European women have polycystic ovaries, but most of those women do not have PCOS. [15]

Environment

PCOS may be related to or worsened by exposures[ clarification needed ] during the prenatal period, [74] [75] [76] epigenetic factors, environmental impacts (especially industrial endocrine disruptors, such as bisphenol A and certain drugs) [77] [78] [79] and the increasing rates of obesity. [78]

Endocrine disruptors are defined as chemicals that can interfere with the endocrine system by mimicking hormones such as estrogen. According to the NIH (National Institute of Health), examples of endocrine disruptors can include dioxins and triclosan. Endocrine disruptors can cause adverse health impacts in animals. [80] Additional research is needed to assess the role that endocrine disruptors may play in disrupting reproductive health in women and possibly triggering or exacerbating PCOS and its related symptoms. [81]

Pathogenesis

Polycystic ovaries develop when the ovaries are stimulated to produce excessive amounts of androgenic hormones, in particular testosterone, by either one or a combination of the following (almost certainly combined with genetic susceptibility): [67]

A majority of women with PCOS have insulin resistance and/or are obese, which is a strong risk factor for insulin resistance, although insulin resistance is a common finding among women with PCOS in normal-weight women as well. [10] [22] [31] Elevated insulin levels contribute to or cause the abnormalities seen in the hypothalamic–pituitary–ovarian axis that lead to PCOS. Hyperinsulinemia increases GnRH pulse frequency, [82] which in turn results in an increase in the LH/FSH ratio [82] [83] increased ovarian androgen production; decreased follicular maturation; and decreased SHBG binding. [82] Furthermore, excessive insulin increases the activity of 17α-hydroxylase, which catalyzes the conversion of progesterone to androstenedione, which is in turn converted to testosterone. The combined effects of hyperinsulinemia contribute to an increased risk of PCOS. [82]

Adipose (fat) tissue possesses aromatase, an enzyme that converts androstenedione to estrone and testosterone to estradiol. The excess of adipose tissue in obese women creates the paradox of having both excess androgens (which are responsible for hirsutism and virilization) and excess estrogens (which inhibit FSH via negative feedback). [84]

The syndrome acquired its most widely used name due to the common sign on ultrasound examination of multiple (poly) ovarian cysts. These "cysts" are in fact immature ovarian follicles. The follicles have developed from primordial follicles, but this development has stopped ("arrested") at an early stage, due to the disturbed ovarian function. The follicles may be oriented along the ovarian periphery, appearing as a 'string of pearls' on ultrasound examination. [85]

PCOS may be associated with chronic inflammation, [86] with several investigators correlating inflammatory mediators with anovulation and other PCOS symptoms. [87] [88] Similarly, there seems to be a relation between PCOS and an increased level of oxidative stress. [89]

Diagnosis

Not every person with PCOS has polycystic ovaries (PCO), nor does everyone with ovarian cysts have PCOS; although a pelvic ultrasound is a major diagnostic tool, it is not the only one. [90] The diagnosis is fairly straightforward using the Rotterdam criteria, even when the syndrome is associated with a wide range of symptoms. [91]

Differential diagnosis

Other causes of irregular or absent menstruation and hirsutism, such as hypothyroidism, congenital adrenal hyperplasia (21-hydroxylase deficiency) (which may cause excessive body hair, deep tone voice and others symptoms similar to hyperandrogenism), Cushing's syndrome, hyperprolactinemia (leading to anovulation), androgen-secreting neoplasms, and other pituitary or adrenal disorders, should be investigated. [22] [24] [92]

Assessment and testing

Standard assessment

  • History-taking, specifically for menstrual pattern, obesity, hirsutism and acne. A clinical prediction rule found that these four questions can diagnose PCOS with a sensitivity of 77.1% (95% confidence interval [CI] 62.7%–88.0%) and a specificity of 93.8% (95% CI 82.8%–98.7%). [93]
  • Gynecologic ultrasonography, specifically looking for small ovarian follicles. These are believed to be the result of disturbed ovarian function with failed ovulation, reflected by the infrequent or absent menstruation that is typical of the condition. In a normal menstrual cycle, one egg is released from a dominant follicle – in essence, a cyst that bursts to release the egg. After ovulation, the follicle remnant is transformed into a progesterone-producing corpus luteum, which shrinks and disappears after approximately 12–14 days. In PCOS, there is a so-called "follicular arrest"; i.e., several follicles develop to a size of 5–7 mm, but not further. No single follicle reaches the preovulatory size (16 mm or more). According to the Rotterdam criteria, which are widely used for diagnosis of PCOS, [10] 12 or more small follicles should be seen in a suspect ovary on ultrasound examination. [21] More recent research suggests that there should be at least 25 follicles in an ovary to designate it as having polycystic ovarian morphology (PCOM) in women aged 18–35 years. [94] The follicles may be oriented in the periphery, giving the appearance of a 'string of pearls'. [95] If a high-resolution transvaginal ultrasonography machine is not available, an ovarian volume of at least 10 ml is regarded as an acceptable definition of having polycystic ovarian morphology. rather than follicle count. [94]
  • Laparoscopic examination may reveal a thickened, smooth, pearl-white outer surface of the ovary. (This would usually be an incidental finding if laparoscopy were performed for some other reason, as it would not be routine to examine the ovaries in this way to confirm a diagnosis of PCOS.) [96]
  • Serum (blood) levels of androgens, including androstenedione and testosterone may be elevated. [22] Dehydroepiandrosterone sulfate (DHEA-S) levels above 700–800 µg/dL are highly suggestive of adrenal dysfunction because DHEA-S is made exclusively by the adrenal glands. [97] [92] The free testosterone level is thought to be the best measure, [92] [98] with approximately 60 per cent of PCOS patients demonstrating supranormal levels. [30]

Some other blood tests are suggestive but not diagnostic. The ratio of LH (luteinizing hormone) to FSH (follicle-stimulating hormone), when measured in international units, is elevated in women with PCOS. Common cut-offs to designate abnormally high LH/FSH ratios are 2:1 [99] or 3:1 [92] as tested on day 3 of the menstrual cycle. The pattern is not very sensitive; a ratio of 2:1 or higher was present in less than 50% of women with PCOS in one study. [99] There are often low levels of sex hormone-binding globulin, [92] in particular among obese or overweight women. [100] Anti-Müllerian hormone (AMH) is increased in PCOS, and may become part of its diagnostic criteria. [101] [102] [103]

Glucose tolerance testing

  • Two-hour oral glucose tolerance test (GTT) in women with risk factors (obesity, family history, history of gestational diabetes) [22] may indicate impaired glucose tolerance (insulin resistance) in 15–33% of women with PCOS. [92] Frank diabetes can be seen in 65–68% of women with this condition. [104] Insulin resistance can be observed in both normal weight and overweight people, although it is more common in the latter (and in those matching the stricter NIH criteria for diagnosis); 50–80% of people with PCOS may have insulin resistance at some level. [22]
  • Fasting insulin level or GTT with insulin levels (also called IGTT). Elevated insulin levels have been helpful to predict response to medication and may indicate women needing higher doses of metformin or the use of a second medication to significantly lower insulin levels. Elevated blood sugar and insulin values do not predict who responds to an insulin-lowering medication, low-glycemic diet, and exercise. Many women with normal levels may benefit from combination therapy. A hypoglycemic response in which the two-hour insulin level is higher and the blood sugar lower than fasting is consistent with insulin resistance. A mathematical derivation known as the HOMAI, calculated from the fasting values in glucose and insulin concentrations, allows a direct and moderately accurate measure of insulin sensitivity (glucose-level x insulin-level/22.5). [105]

Management

PCOS has no cure. [5] Treatment may involve lifestyle changes such as weight loss and exercise. [10] [11]

Recent research suggests that daily exercise including both aerobic and strength activities can improve hormone imbalances. [106]

Birth control pills may help with improving the regularity of periods, excess hair growth, and acne. [12] Combined oral contraceptives are especially effective, and used as the first-line of treatment to reduce acne and hirsutism, and regulate menstrual cycle. This is especially the case of adolescents. [106]

Metformin and anti-androgens may also help. [12] Other typical acne treatments and hair removal techniques may be used. [12] Efforts to improve fertility include weight loss, metformin, and ovulation induction using clomiphene or letrozole. [107] In vitro fertilization is used by some in whom other measures are not effective. [107]

Certain cosmetic procedures may also help alleviate symptoms in some cases. For example, the use of laser hair removal, electrolysis, or general waxing, plucking and shaving are all effective methods for reducing hirsutism. [35] The primary treatments for PCOS include lifestyle changes and use of medications. [108]

Goals of treatment may be considered under four categories:[ citation needed ]

In each of these areas, there is considerable debate as to the optimal treatment. One of the major factors underlying the debate is the lack of large-scale clinical trials comparing different treatments. Smaller trials tend to be less reliable and hence may produce conflicting results. General interventions that help to reduce weight or insulin resistance can be beneficial for all these aims, because they address what is believed to be the underlying cause. [109] As PCOS appears to cause significant emotional distress, appropriate support may be useful. [110]

Diet

Where PCOS is associated with being overweight or obesity, successful weight loss is the most effective method of restoring normal ovulation/menstruation. The American Association of Clinical Endocrinologists guidelines recommend a goal of achieving 10–15% weight loss or more, which improves insulin resistance and all[ clarification needed ] hormonal disorders. [111] Still, many women find it very difficult to achieve and sustain significant weight loss. Insulin resistance itself can cause increased food cravings and lower energy levels, which can make it difficult to lose weight on a regular weight-loss diet. A scientific review in 2013 found similar improvements in weight, body composition and pregnancy rate, menstrual regularity, ovulation, hyperandrogenism, insulin resistance, lipids, and quality of life to occur with weight loss, independent of diet composition. [112] Still, a low GI diet, in which a significant portion of total carbohydrates is obtained from fruit, vegetables, and whole-grain sources, has resulted in greater menstrual regularity than a macronutrient-matched healthy diet. [112]

Reducing intake of food groups that cause inflammation, such as dairy, sugars and simple carbohydrates, can be beneficial. [35]

A mediterranean diet is often very effective due to its anti-inflammatory and anti-oxidative properties. [106]

Vitamin D deficiency may play some role in the development of the metabolic syndrome, and treatment of any such deficiency is indicated. [113] [114] However, a systematic review of 2015 found no evidence that vitamin D supplementation reduced or mitigated metabolic and hormonal dysregulations in PCOS. [115] As of 2012, interventions using dietary supplements to correct metabolic deficiencies in people with PCOS had been tested in small, uncontrolled and nonrandomized clinical trials; the resulting data are insufficient to recommend their use. [116]

Medications

Medications for PCOS include oral contraceptives and metformin. The oral contraceptives increase sex hormone binding globulin production, which increases binding of free testosterone. This reduces the symptoms of hirsutism caused by high testosterone and regulates return to normal menstrual periods. [113] Anti-androgens such as finasteride, flutamide, spironolactone, and bicalutamide do not show advantages over oral contraceptives, but could be an option for people who do not tolerate them. [117] Finasteride is the only oral medication for the treatment of androgenic alopecia, that is FDA approved. [35]

Metformin is a medication commonly used in type 2 diabetes mellitus to reduce insulin resistance, and is used off label (in the UK, US, AU and EU) to treat insulin resistance seen in PCOS. In many cases, metformin also supports ovarian function and return to normal ovulation. [113] [118] A newer insulin resistance medication class, the thiazolidinediones (glitazones), have shown equivalent efficacy to metformin, but metformin has a more favorable side effect profile. [119] [120] The United Kingdom's National Institute for Health and Clinical Excellence recommended in 2004 that women with PCOS and a body mass index above 25 be given metformin when other therapy has failed to produce results. [121] [122] Metformin may not be effective in every type of PCOS, and therefore there is some disagreement about whether it should be used as a general first line therapy. [123] In addition to this, metformin is associated with several unpleasant side effects: including abdominal pain, metallic taste in the mouth, diarrhoea and vomiting. [124] Metformin is thought to be safe to use during pregnancy (pregnancy category B in the US). [125] A review in 2014 concluded that the use of metformin does not increase the risk of major birth defects in women treated with metformin during the first trimester. [126] Liraglutide may reduce weight and waist circumference in people with PCOS more than other medications. [127] The use of statins in the management of underlying metabolic syndrome remains unclear. [108]

It can be difficult to become pregnant with PCOS because it causes irregular ovulation. Medications to induce fertility when trying to conceive include the ovulation inducer clomiphene or pulsatile leuprorelin. Evidence from randomised controlled trials suggests that in terms of live birth, metformin may be better than placebo, and metform plus clomiphene may be better than clomiphene alone, but that in both cases women may be more likely to experience gastrointestinal side effects with metformin. [128]

Infertility

Not all people with PCOS have difficulty becoming pregnant. But some individuals with PCOS may have difficulty getting pregnant since their body does not produce the hormones necessary for regular ovulation. [129] PCOS might also increase the risk of miscarriage or premature delivery. However, it is possible to have a normal pregnancy. Including medical care and a healthy lifestyle to follow.[ citation needed ]

For those that do, anovulation or infrequent ovulation is a common cause and PCOS is the main cause of anovulatory infertility. [130] Other factors include changed levels of gonadotropins, hyperandrogenemia, and hyperinsulinemia. [131] Like women without PCOS, women with PCOS that are ovulating may be infertile due to other causes, such as tubal blockages due to a history of sexually transmitted diseases. [132]

For overweight anovulatory women with PCOS, weight loss and diet adjustments, especially to reduce the intake of simple carbohydrates, are associated with resumption of natural ovulation. [133] Digital health interventions have been shown to be particularly effective in providing combined therapy to manage PCOS through both lifestyle changes and medication. [134]

Femara is an alternative medicine that raises FSH levels and promote the development of the follicle. [35]

For those women that after weight loss still are anovulatory or for anovulatory lean women, then ovulation induction using the medications letrozole or clomiphene citrate are the principal treatments used to promote ovulation. [135] [136] [137] Clomiphene can cause mood swings and abdominal cramping for some. [35]

Previously, the anti-diabetes medication metformin was recommended treatment for anovulation, but it appears less effective than letrozole or clomiphene. [138] [139]

For women not responsive to letrozole or clomiphene and diet and lifestyle modification, there are options available including assisted reproductive technology procedures such as controlled ovarian hyperstimulation with follicle-stimulating hormone (FSH) injections followed by in vitro fertilisation (IVF). [140]

Though surgery is not commonly performed, the polycystic ovaries can be treated with a laparoscopic procedure called "ovarian drilling" (puncture of 4–10 small follicles with electrocautery, laser, or biopsy needles), which often results in either resumption of spontaneous ovulations [113] or ovulations after adjuvant treatment with clomiphene or FSH. [141] (Ovarian wedge resection is no longer used as much due to complications such as adhesions and the presence of frequently effective medications.) There are, however, concerns about the long-term effects of ovarian drilling on ovarian function. [113]

Mental Health

Although women with PCOS are far more likely to have depression than women without, the evidence for anti-depressant use in women with PCOS remains inconclusive. [142] However, the pathophysiology of depression and mental stress during PCOS is linked to various changes including psychological changes such as high activity of pro-inflammatory markers and immune system during stress. [143]

PCOS is associated with other mental health related conditions besides depression such as anxiety, bipolar disorder, and obsessive–compulsive disorder. [33]

Hirsutism and acne

When appropriate (e.g., in women of child-bearing age who require contraception), a standard contraceptive pill is frequently effective in reducing hirsutism. [113] Progestogens such as norgestrel and levonorgestrel should be avoided due to their androgenic effects. [113] Metformin combined with an oral contraceptive may be more effective than either metformin or the oral contraceptive on its own. [144]

In the case of taking medication for acne, Kelly Morrow-Baez PHD, in her exposition titled Thriving with PCOS, informs that it "takes time for medications to adjust hormone levels, and once those hormone levels are adjusted, it takes more time still for pores to be unclogged of overproduced oil and for any bacterial infections under the skin to clear up before you will see discernible results." (p. 138) [35]

Other medications with anti-androgen effects include flutamide, [145] and spironolactone, [113] which can give some improvement in hirsutism. Metformin can reduce hirsutism, perhaps by reducing insulin resistance, and is often used if there are other features such as insulin resistance, diabetes, or obesity that should also benefit from metformin. Eflornithine (Vaniqa) is a medication that is applied to the skin in cream form, and acts directly on the hair follicles to inhibit hair growth. It is usually applied to the face. [113] 5-alpha reductase inhibitors (such as finasteride and dutasteride) may also be used; [146] they work by blocking the conversion of testosterone to dihydrotestosterone (the latter of which responsible for most hair growth alterations and androgenic acne).

Although these agents have shown significant efficacy in clinical trials (for oral contraceptives, in 60–100% of individuals [113] ), the reduction in hair growth may not be enough to eliminate the social embarrassment of hirsutism, or the inconvenience of plucking or shaving. Individuals vary in their response to different therapies. It is usually worth trying other medications if one does not work, but medications do not work well for all individuals. [147]

Menstrual irregularity

If fertility is not the primary aim, then menstruation can usually be regulated with a contraceptive pill. [113] The purpose of regulating menstruation, in essence, is for the patient's convenience, and perhaps their sense of well-being; there is no medical requirement for regular periods, as long as they occur sufficiently often. [148]

If a regular menstrual cycle is not desired, then therapy for an irregular cycle is not necessarily required. Most experts say that, if a menstrual bleed occurs at least every three months, then the endometrium (womb lining) is being shed sufficiently often to prevent an increased risk of endometrial abnormalities or cancer. [149] If menstruation occurs less often or not at all, some form of progestogen replacement is recommended. [146]

Alternative medicine

A 2017 review concluded that while both myo-inositol and D-chiro-inositols may regulate menstrual cycles and improve ovulation, there is a lack of evidence regarding effects on the probability of pregnancy. [150] [151] A 2012 and 2017 review have found myo-inositol supplementation appears to be effective in improving several of the hormonal disturbances of PCOS. [152] [153] Myo-inositol reduces the amount of gonadotropins and the length of controlled ovarian hyperstimulation in women undergoing in vitro fertilization. [154] A 2011 review found not enough evidence to conclude any beneficial effect from D-chiro-inositol. [155] There is insufficient evidence to support the use of acupuncture, current studies are inconclusive and there's a need for additional randomized controlled trials. [156] [157]

Epidemiology

PCOS is the most common endocrine disorder among women between the ages of 18 and 44. [22] It affects approximately 2% to 20% of this age group depending on how it is defined. [8] [13] When someone is infertile due to lack of ovulation, PCOS is the most common cause and could guide to patients' diagnosis. [4] The earliest known description of what is now recognized as PCOS dates from 1721 in Italy. [158]

The prevalence of PCOS depends on the choice of diagnostic criteria. The World Health Organization estimates that it affects 116 million women worldwide as of 2010 (3.4% of women). [159] Another estimate indicates that 7% of women of reproductive age are affected. [160] Another study using the Rotterdam criteria found that about 18% of women had PCOS, and that 70% of them were previously undiagnosed. [22] Prevalence also varies across countries due to lack of large-scale scientific studies; India, for example, has a purported rate of 1 in 5 women having PCOS. [161]

There are few studies that have investigated the racial differences in cardiometabolic factors in women with PCOS. There is also limited data on the racial differences in the risk of metabolic syndrome and cardiovascular disease in adolescents and young adults with PCOS. [162] The first study to comprehensively examine racial differences discovered notable racial differences in risk factors for cardiovascular disease. African American women were found to be significantly more obese, with a significantly higher prevalence of metabolic syndrome compared to white adult women with PCOS. [163] It is important for the further research of racial differences among women with PCOS, to ensure that every woman that is affected by PCOS has the available resources for management. [164] [165]

Ultrasonographic findings of polycystic ovaries are found in 8–25% of women non-affected by the syndrome. [166] [167] [168] [169] 14% women on oral contraceptives are found to have polycystic ovaries. [167] Ovarian cysts are also a common side effect of levonorgestrel-releasing intrauterine devices (IUDs). [170]

There are few studies that have investigated the racial differences in cardiometabolic factors in women with PCOS. [171]

History

The condition was first described in 1935 by American gynecologists Irving F. Stein, Sr. and Michael L. Leventhal, from whom its original name of Stein–Leventhal syndrome is taken. [90] [21] Stein and Leventhal first described PCOS as an endocrine disorder in the United States, and since then, it has become recognized as one of the most common causes of oligo ovulatory infertility among women. [49]

The earliest published description of a person with what is now recognized as PCOS was in 1721 in Italy. [158] Cyst-related changes to the ovaries were described in 1844. [158]

Etymology

Other names for this syndrome include polycystic ovarian syndrome, polycystic ovary disease, functional ovarian hyperandrogenism, ovarian hyperthecosis, sclerocystic ovary syndrome, and Stein–Leventhal syndrome. The eponymous last option is the original name; it is now used, if at all, only for the subset of women with all the symptoms of amenorrhea with infertility, hirsutism, and enlarged polycystic ovaries. [90]

Most common names for this disease derive from a typical finding on medical images, called a polycystic ovary. A polycystic ovary has an abnormally large number of developing eggs visible near its surface, looking like many small cysts. [90]

Society and culture

In 2005, 4 million cases of PCOS were reported in the US, costing $4.36 billion in healthcare costs. [172] In 2016 out of the National Institute Health's research budget of $32.3 billion for that year, 0.1% was spent on PCOS research. [173] Among those aged between 14 and 44, PCOS is conservatively estimated to cost $4.37 billion per year. [23]

As opposed to women in the general population, women with PCOS experience higher rates of depression and anxiety. International guidelines and Indian guidelines suggest psychosocial factors should be considered in women with PCOS, as well as screenings for depression and anxiety. [174] Globally, this aspect has been increasingly focused on because it reflects the true impact of PCOS on the lives of patients. Research shows that PCOS adversely impacts a patient's quality of life. [174]

Public figures

A number of celebrities and public figures have spoken about their experiences with PCOS, including:

See also

Related Research Articles

<span class="mw-page-title-main">Hirsutism</span> Excessive hair growth on parts of the body where hair is usually minimal

Hirsutism is excessive body hair on parts of the body where hair is normally absent or minimal. The word is from early 17th century: from Latin hirsutus meaning "hairy". It usually refers to a male pattern of hair growth in a female that may be a sign of a more serious medical condition, especially if it develops well after puberty. Cultural stigma against hirsutism can cause much psychological distress and social difficulty. Discrimination based on facial hirsutism often leads to the avoidance of social situations and to symptoms of anxiety and depression.

Amenorrhea is the absence of a menstrual period in a female who has reached reproductive age. Physiological states of amenorrhoea are seen, most commonly, during pregnancy and lactation (breastfeeding). Outside the reproductive years, there is absence of menses during childhood and after menopause.

<span class="mw-page-title-main">Luteinizing hormone</span> Gonadotropin secreted by the adenohypophysis

Luteinizing hormone is a hormone produced by gonadotropic cells in the anterior pituitary gland. The production of LH is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus. In females, an acute rise of LH known as an LH surge, triggers ovulation and development of the corpus luteum. In males, where LH had also been called interstitial cell–stimulating hormone (ICSH), it stimulates Leydig cell production of testosterone. It acts synergistically with follicle-stimulating hormone (FSH).

Anovulation is when the ovaries do not release an oocyte during a menstrual cycle. Therefore, ovulation does not take place. However, a woman who does not ovulate at each menstrual cycle is not necessarily going through menopause. Chronic anovulation is a common cause of infertility.

Pubarche refers to the first appearance of pubic hair at puberty and it also marks the beginning of puberty. It is one of the physical changes of puberty and can occur independently of complete puberty. The early stage of sexual maturation, also known as adrenarche, is marked by characteristics including the development of pubic hair, axillary hair, adult apocrine body odor, acne, and increased oiliness of hair and skin. The Encyclopedia of Child and Adolescent Health corresponds SMR2 with pubarche, defining it as the development of pubic hair that occurs at a mean age of 11.6 years in females and 12.6 years in males. It further describes that pubarche's physical manifestation is vellus hair over the labia or the base of the penis. See Table 1 for the entirety of the sexual maturity rating description.

<span class="mw-page-title-main">Hyperandrogenism</span> Medical condition

Hyperandrogenism is a medical condition characterized by high levels of androgens. It is more common in women than men. Symptoms of hyperandrogenism may include acne, seborrhea, hair loss on the scalp, increased body or facial hair, and infrequent or absent menstruation. Complications may include high blood cholesterol and diabetes. It occurs in approximately 5% of women of reproductive age.

Fertility medications, also known as fertility drugs, are medications which enhance reproductive fertility. For women, fertility medication is used to stimulate follicle development of the ovary. There are very few fertility medication options available for men.

<span class="mw-page-title-main">Anti-Müllerian hormone</span> Mammalian protein found in humans

Anti-Müllerian hormone (AMH), also known as Müllerian-inhibiting hormone (MIH), is a glycoprotein hormone structurally related to inhibin and activin from the transforming growth factor beta superfamily, whose key roles are in growth differentiation and folliculogenesis. In humans, it is encoded by the AMH gene, on chromosome 19p13.3, while its receptor is encoded by the AMHR2 gene on chromosome 12.

<span class="mw-page-title-main">Follicular atresia</span>

Follicular atresia refers to the process in which a follicle fails to develop, thus preventing it from ovulating and releasing an egg. It is a normal, naturally occurring progression that occurs as mammalian ovaries age. Approximately 1% of mammalian follicles in ovaries undergo ovulation and the remaining 99% of follicles go through follicular atresia as they cycle through the growth phases. In summary, follicular atresia is a process that leads to the follicular loss and loss of oocytes, and any disturbance or loss of functionality of this process can lead to many other conditions.

<span class="mw-page-title-main">Pattern hair loss</span> Medical condition

Pattern hair loss is a hair loss condition that primarily affects the top and front of the scalp. In male-pattern hair loss (MPHL), the hair loss typically presents itself as either a receding front hairline, loss of hair on the crown (vertex) of the scalp, or a combination of both. Female-pattern hair loss (FPHL) typically presents as a diffuse thinning of the hair across the entire scalp.

Ovulation induction is the stimulation of ovulation by medication. It is usually used in the sense of stimulation of the development of ovarian follicles to reverse anovulation or oligoovulation.

Free Androgen Index (FAI) is a ratio used to determine abnormal androgen status in humans. The ratio is the total testosterone level divided by the sex hormone binding globulin (SHBG) level, and then multiplying by a constant, usually 100. The concentrations of testosterone and SHBG are normally measured in nanomols per liter. FAI has no unit.

Masculinizing hormone therapy, also known as transmasculine hormone therapy or female-to-male hormone therapy, is a form of hormone therapy and gender affirming therapy which is used to change the secondary sexual characteristics of transgender people from feminine or androgynous to masculine. It is a common type of transgender hormone therapy, and is predominantly used to treat transgender men and other transmasculine individuals who were assigned female at birth. Some intersex people also receive this form of therapy, either starting in childhood to confirm the assigned sex or later if the assignment proves to be incorrect.

Hyperthecosis, or ovarian hyperthecosis, is hyperplasia of the theca interna of the ovary. Hyperthecosis occurs when an area of luteinization occurs along with stromal hyperplasia. The luteinized cells produce androgens, which may lead to hirsutism and virilization in affected women.

Ovarian drilling, also known as multiperforation or laparoscopic ovarian diathermy, is a surgical technique of puncturing the membranes surrounding the ovary with a laser beam or a surgical needle using minimally invasive laparoscopic procedures. It differs from ovarian wedge resection, which involves the cutting of tissue. Minimally invasive ovarian drilling procedures have replaced wedge resections. Ovarian drilling is preferred to wedge resection because cutting into the ovary can cause adhesions which may complicate postoperative outcomes. Ovarian drilling and ovarian wedge resection are treatment options to reduce the amount of androgen producing tissue in women with polycystic ovarian syndrome (PCOS). PCOS is the primary cause of anovulation, which results in female infertility. The induction of mono-ovulatory cycles can restore fertility.

Infertility in polycystic ovary disease (PCOS) is a hormonal imbalance in women that is thought to be one of the leading causes of female infertility. Polycystic ovary syndrome causes more than 75% of cases of anovulatory infertility.

Obesity is defined as an abnormal accumulation of body fat, usually 20% or more over an individual's ideal body weight. This is often described as a body mass index (BMI) over 30. However, BMI does not account for whether the excess weight is fat or muscle, and is not a measure of body composition. For most people, however, BMI is an indication used worldwide to estimate nutritional status. Obesity is usually the result of consuming more calories than the body needs and not expending that energy by doing exercise. There are genetic causes and hormonal disorders that cause people to gain significant amounts of weight but this is rare. People in the obese category are much more likely to suffer from fertility problems than people of normal healthy weight.

<span class="mw-page-title-main">HAIR-AN syndrome</span> Medical condition

The HAIR-AN syndrome is a rare subtype of polycystic ovary syndrome (PCOS) characterized by hyperandrogenism (HA), insulin resistance (IR) and acanthosis nigricans (AN). The symptoms of the HAIR-AN syndrome are largely due to severe insulin resistance, which can be secondary to blocking antibodies against the insulin receptor or genetically absent/reduced insulin receptor number/function. Insulin resistance leads to hyperinsulinemia which, in turn, leads to an excess production of androgen hormones by the ovaries. High levels of androgen hormones (hyperandrogenism) in females causes excessive hair growth, acne and irregular menstruation. Patients with both underlying mechanisms of insulin resistance may have more severe hyperandrogenism. Insulin resistance is also associated with diabetes, heart disease and excessive darkening of the skin

Gonadotropin surge-attenuating factor (GnSAF) is a nonsteroidal ovarian hormone produced by the granulosa cells of small antral ovarian follicles in females. GnSAF is involved in regulating the secretion of luteinizing hormone (LH) from the anterior pituitary and the ovarian cycle. During the early to mid-follicular phase of the ovarian cycle, GnSAF acts on the anterior pituitary to attenuate LH release, limiting the secretion of LH to only basal levels. At the transition between follicular and luteal phase, GnSAF bioactivity declines sufficiently to permit LH secretion above basal levels, resulting in the mid-cycle LH surge that initiates ovulation. In normally ovulating women, the LH surge only occurs when the oocyte is mature and ready for extrusion. GnSAF bioactivity is responsible for the synchronised, biphasic nature of LH secretion.

Ovarian follicle dominance is the process where one or more follicles are selected per cycle to ovulate.

References

  1. ↑ Kollmann M, Martins WP, Raine-Fenning N (2014). "Terms and thresholds for the ultrasound evaluation of the ovaries in women with hyperandrogenic anovulation". Human Reproduction Update. 20 (3): 463–464. doi: 10.1093/humupd/dmu005 . PMID   24516084.
  2. ↑ Legro RS (2017). "Stein-Leventhal syndrome". Encyclopedia Britannica. Retrieved 30 January 2021.[ better source needed ]
  3. 1 2 3 "What are the symptoms of PCOS?". Eunice Kennedy Shriver National Institute of Child Health and Human Development . 29 September 2022.
  4. 1 2 3 4 5 "Polycystic Ovary Syndrome (PCOS): Condition Information". National Institute of Child Health and Human Development. January 31, 2017. Retrieved 19 November 2018.
  5. 1 2 "Is there a cure for PCOS?". Eunice Kennedy Shriver National Institute of Child Health and Human Development . 31 January 2017.
  6. 1 2 De Leo V, Musacchio MC, Cappelli V, Massaro MG, Morgante G, Petraglia F (July 2016). "Genetic, hormonal and metabolic aspects of PCOS: an update". Reproductive Biology and Endocrinology (Review). 14 (1): 38. doi: 10.1186/s12958-016-0173-x . PMC   4947298 . PMID   27423183.
  7. 1 2 3 4 5 Diamanti-Kandarakis E, Kandarakis H, Legro RS (August 2006). "The role of genes and environment in the etiology of PCOS". Endocrine. 30 (1): 19–26. doi:10.1385/ENDO:30:1:19. PMID   17185788. S2CID   21220430.
  8. 1 2 3 4 "What causes PCOS?". Eunice Kennedy Shriver National Institute of Child Health and Human Development . 29 September 2022.
  9. 1 2 3 "How do health care providers diagnose PCOS?". Eunice Kennedy Shriver National Institute of Child Health and Human Development . 29 September 2022.
  10. 1 2 3 4 Mortada R, Williams T (August 2015). "Metabolic Syndrome: Polycystic Ovary Syndrome". FP Essentials (Review). 435: 30–42. PMID   26280343.
  11. 1 2 Giallauria F, Palomba S, Vigorito C, Tafuri MG, Colao A, Lombardi G, Orio F (July 2009). "Androgens in polycystic ovary syndrome: the role of exercise and diet". Seminars in Reproductive Medicine (Review). 27 (4): 306–315. doi:10.1055/s-0029-1225258. PMID   19530064. S2CID   260321191.
  12. 1 2 3 4 National Institutes of Health (NIH) (2014-07-14). "Treatments to Relieve Symptoms of PCOS". Archived from the original on 2 April 2015. Retrieved 13 March 2015.
  13. 1 2 Pal L, ed. (2013). "Diagnostic Criteria and Epidemiology of PCOS". Polycystic Ovary Syndrome Current and Emerging Concepts. Dordrecht: Springer. p. 7. ISBN   978-1-4614-8394-6. Archived from the original on 2017-09-10.
  14. ↑ Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E (November 2015). "American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1". Endocrine Practice. 21 (11): 1291–1300. doi: 10.4158/EP15748.DSC . PMID   26509855.
  15. 1 2 Dunaif A, Fauser BC (November 2013). "Renaming PCOS--a two-state solution". The Journal of Clinical Endocrinology and Metabolism. 98 (11): 4325–4328. doi:10.1210/jc.2013-2040. PMC   3816269 . PMID   24009134. Around 20% of European women have polycystic ovaries (the prevalence is even higher in some other populations) but approximately two-thirds of these women do not have PCOS
  16. ↑ Khan MJ, Ullah A, Basit S. Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. Appl Clin Genet. 2019 Dec 24;12:249-260. doi: 10.2147/TACG.S200341. PMID 31920361; PMCID: PMC6935309.
  17. ↑ Crespo RP, Bachega TA, Mendonça BB, Gomes LG (June 2018). "An update of genetic basis of PCOS pathogenesis". Archives of Endocrinology and Metabolism. 62 (3): 352–361. doi: 10.20945/2359-3997000000049 . PMC   10118782 . PMID   29972435. S2CID   49681196.
  18. ↑ Muscogiuri G, Altieri B, de Angelis C, Palomba S, Pivonello R, Colao A, Orio F (September 2017). "Shedding new light on female fertility: The role of vitamin D". Reviews in Endocrine & Metabolic Disorders. 18 (3): 273–283. doi:10.1007/s11154-017-9407-2. PMID   28102491. S2CID   33422072.
  19. 1 2 Lentscher JA, Slocum B, Torrealday S (March 2021). "Polycystic Ovarian Syndrome and Fertility". Clinical Obstetrics and Gynecology. 64 (1): 65–75. doi:10.1097/GRF.0000000000000595. PMID   33337743. S2CID   229323594.
  20. ↑ Wolf WM, Wattick RA, Kinkade ON, Olfert MD (November 2018). "Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity". International Journal of Environmental Research and Public Health. 15 (11): 2589. doi: 10.3390/ijerph15112589 . PMC   6266413 . PMID   30463276. indigenous Australian women could have a prevalence as high as 26%
  21. 1 2 3 4 5 6 7 8 Polycystic Ovarian Syndrome at eMedicine
  22. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Teede H, Deeks A, Moran L (June 2010). "Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan". BMC Medicine. 8 (1): 41. doi: 10.1186/1741-7015-8-41 . PMC   2909929 . PMID   20591140.
  23. 1 2 Azziz R (March 2006). "Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature". The Journal of Clinical Endocrinology and Metabolism. 91 (3): 781–785. doi: 10.1210/jc.2005-2153 . PMID   16418211.
  24. 1 2 Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (January 2004). "Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS)". Human Reproduction. 19 (1): 41–47. doi: 10.1093/humrep/deh098 . PMID   14688154.
  25. ↑ Carmina E (February 2004). "Diagnosis of polycystic ovary syndrome: from NIH criteria to ESHRE-ASRM guidelines". Minerva Ginecologica. 56 (1): 1–6. PMID   14973405. NAID   10025610607.
  26. ↑ Hart R, Hickey M, Franks S (October 2004). "Definitions, prevalence and symptoms of polycystic ovaries and polycystic ovary syndrome". Best Practice & Research. Clinical Obstetrics & Gynaecology. 18 (5): 671–683. doi:10.1016/j.bpobgyn.2004.05.001. PMID   15380140.
  27. 1 2 "What We Talk About When We Talk About PCOS". www.vice.com. 23 January 2019. Retrieved 2022-01-19.
  28. ↑ "Polycystic Ovary Syndrome (PCOS)". www.hopkinsmedicine.org. 2022-02-28. Retrieved 2023-02-09.
  29. ↑ Cortet-Rudelli C, Dewailly D (Sep 21, 2006). "Diagnosis of Hyperandrogenism in Female Adolescents". Hyperandrogenism in Adolescent Girls. Armenian Health Network, Health.am. Archived from the original on 2007-09-30. Retrieved 2006-11-21.
  30. 1 2 Huang A, Brennan K, Azziz R (April 2010). "Prevalence of hyperandrogenemia in the polycystic ovary syndrome diagnosed by the National Institutes of Health 1990 criteria". Fertility and Sterility. 93 (6): 1938–1941. doi:10.1016/j.fertnstert.2008.12.138. PMC   2859983 . PMID   19249030.
  31. 1 2 Nafiye Y, Sevtap K, Muammer D, Emre O, Senol K, Leyla M (April 2010). "The effect of serum and intrafollicular insulin resistance parameters and homocysteine levels of nonobese, nonhyperandrogenemic polycystic ovary syndrome patients on in vitro fertilization outcome". Fertility and Sterility. 93 (6): 1864–1869. doi: 10.1016/j.fertnstert.2008.12.024 . PMID   19171332.
  32. 1 2 Pasquali R (2018). "Lifestyle Interventions and Natural and Assisted Reproduction in Patients with PCOS". Infertility in Women with Polycystic Ovary Syndrome. Cham: Springer International Publishing. pp. 169–180. doi:10.1007/978-3-319-45534-1_13. ISBN   978-3-319-45533-4.
  33. 1 2 Brutocao C, Zaiem F, Alsawas M, Morrow AS, Murad MH, Javed A (November 2018). "Psychiatric disorders in women with polycystic ovary syndrome: a systematic review and meta-analysis". Endocrine. 62 (2): 318–325. doi:10.1007/s12020-018-1692-3. PMID   30066285. S2CID   51889051.
  34. ↑ Devi T (2018). "Lifestyle Modifications in Polycystic Ovarian Syndrome". Decoding Polycystic Ovarian Syndrome (PCOS). Jaypee Brothers Medical Publishers (P) Ltd. p. 195. doi:10.5005/jp/books/13089_17. ISBN   978-93-86322-85-2.
  35. 1 2 3 4 5 6 7 Morrow-Baez K (2018). Thriving with PCOS: Lifestyle Strategies to Successfully Manage Polycystic Ovary Syndrome. Rowman & Littlefield Publishers.
  36. ↑ Rasquin LI, Anastasopoulou C, Mayrin JV (2023). "Polycystic Ovarian Disease". StatPearls. StatPearls Publishing. PMID   29083730.
  37. ↑ Sam S (February 2015). "Adiposity and metabolic dysfunction in polycystic ovary syndrome". Hormone Molecular Biology and Clinical Investigation. 21 (2): 107–116. doi:10.1515/hmbci-2015-0008. PMID   25781555. S2CID   23592351.
  38. ↑ Corbould A (October 2008). "Effects of androgens on insulin action in women: is androgen excess a component of female metabolic syndrome?". Diabetes/Metabolism Research and Reviews. 24 (7): 520–532. doi:10.1002/dmrr.872. PMID   18615851. S2CID   24630977.
  39. ↑ Goyal M, Dawood AS (2017). "Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review". Journal of Human Reproductive Sciences. 10 (3): 154–161. doi: 10.4103/jhrs.JHRS_77_17 . PMC   5672719 . PMID   29142442.
  40. ↑ Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S (2019). "Obese and Non-obese Polycystic Ovarian Syndrome: Comparison of Clinical, Metabolic, Hormonal Parameters, and their Differential Response to Clomiphene". Indian Journal of Endocrinology and Metabolism. 23 (2): 257–262. doi: 10.4103/ijem.IJEM_637_18 . PMC   6540884 . PMID   31161114.
  41. ↑ Johnstone E, Cannon-Albright L, Peterson CM, Allen-Brady K (July 2018). "Lean PCOS may be a genetically distinct from obese PCOS: lean women with polycystic ovary syndrome and their relatives have no increased risk of T2DM". Human Reproduction. 33. Oxford, England: Oxford Univ Press: 454. doi:10.26226/morressier.5af300b3738ab10027aa99cd. S2CID   242055977.
  42. ↑ Goyal M, Dawood AS (2017). "Debates Regarding Lean Patients with Polycystic Ovary Syndrome: A Narrative Review". Journal of Human Reproductive Sciences. 10 (3): 154–161. doi: 10.4103/jhrs.jhrs_77_17 . PMC   5672719 . PMID   29142442.
  43. 1 2 Mazze R, Strock ES, Simonson GD, Bergenstal RM (11 January 2007). "Type 2 Diabetes and Metabolic Syndrome in Children and Adolescents". Staged Diabetes Management: A Systematic Approach (2nd ed.). John Wiley & Sons. pp. 213–. ISBN   978-0-470-06171-8. OCLC   1039172275. Diagnosis and treatment. The first diagnostic test [of PCOS] is measurement of total testosterone and free testosterone by radioimmunoassay. If total testosterone is between 50 ng/dL and 200 ng/dL above normal (<2.5 ng/dL) PCOS is present. If >200 ng/dL then serum DHEA-S should be measured. If total testosterone or DHEA-S >700 μg/dL then rule out an ovarian or adrenal tumor. These tests should be followed by tests for hypothyroidism, hyperprolactinemia, and adrenal hyperplasia.
  44. 1 2 Loh HH, Yee A, Loh HS, Kanagasundram S, Francis B, Lim LL (September 2020). "Sexual dysfunction in polycystic ovary syndrome: a systematic review and meta-analysis". Hormones (Athens). 19 (3): 413–423. doi:10.1007/s42000-020-00210-0. PMID   32462512. S2CID   218898082. A total of 5366 women with PCOS from 21 studies were included. [...] Women with PCOS [...] [had higher] serum total testosterone level (2.34 ± 0.58 nmol/L vs 1.57 ± 0.60 nmol/L, p < 0.001) compared with women without PCOS. [...] PCOS is characterized by high levels of androgens (dehydroepiandrosterone, androstenedione, and testosterone) and luteinizing hormone (LH), and increased LH/follicle stimulating hormone (FSH) ratio [52].
  45. 1 2 Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS (August 1995). "Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients". Hum Reprod. 10 (8): 2107–11. doi:10.1093/oxfordjournals.humrep.a136243. PMID   8567849. The criteria for the diagnosis of the polycystic ovary syndrome (PCOS) have still not been agreed universally. A population of 1741 women with PCOS were studied, all of whom had polycystic ovaries seen by ultrasound scan. The frequency distributions of the serum concentrations of [...] testosterone [...] were determined and compared with the symptoms and signs of PCOS. [...] A rising serum concentration of testosterone [mean and 95th percentiles 2.6 (1.1-4.8) nmol/1] was associated with an increased risk of hirsutism, infertility and cycle disturbance. [...] If the serum testosterone concentration is >4.8 nmol/1, other causes of hyperandrogenism should be excluded.
  46. ↑ Steinberger E, Ayala C, Hsi B, Smith KD, Rodriguez-Rigau LJ, Weidman ER, Reimondo GG (1998). "Utilization of commercial laboratory results in management of hyperandrogenism in women". Endocr Pract. 4 (1): 1–10. doi:10.4158/EP.4.1.1. PMID   15251757.
  47. ↑ Legro RS, Schlaff WD, Diamond MP, Coutifaris C, Casson PR, Brzyski RG, Christman GM, Trussell JC, Krawetz SA, Snyder PJ, Ohl D, Carson SA, Steinkampf MP, Carr BR, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Myers ER, Santoro N, Eisenberg E, Zhang M, Zhang H (December 2010). "Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism". J Clin Endocrinol Metab. 95 (12): 5305–13. doi:10.1210/jc.2010-1123. PMC   2999971 . PMID   20826578. Design and Setting: We conducted a blinded laboratory study including masked duplicate samples at three laboratories—two academic (University of Virginia, RIA; and Mayo Clinic, LC/MS) and one commercial (Quest, LC/MS). Participants and Interventions: Baseline testosterone levels from 596 women with PCOS who participated in a large, multicenter, randomized controlled infertility trial performed at academic health centers in the United States were run by varying assays, and results were compared. [...] The median testosterone level by RIA was 50 ng/dl (25th–75th percentile, 34–71 ng/dl); by LC/MS at Mayo, 47 ng/dl (25th–75th percentile, 34–65 ng/dl); and by LC/MS at Quest, 41 ng/dl (25th–75th percentile, 27–58 ng/dl) (Fig. 1). The minimum and maximum values detected by RIA were 8 and 189 ng/dl, respectively; by LC/MS at Mayo, 12 and 184 ng/dl, respectively; and by LC/MS at Quest, 1 and 205 ng/dl, respectively. [...] Our sample size was robust and the largest study to date examining quality control of total testosterone serum levels in women.
  48. ↑ Carmina E, Stanczyk FZ, Lobo RA (2019). "Evaluation of Hormonal Status". In Strauss JF, Barbieri RL (eds.). Yen and Jaffe's Reproductive Endocrinology: Physiology, Pathophysiology, and Clinical Management (8th ed.). Elsevier. pp. 887–915.e4. doi:10.1016/B978-0-323-47912-7.00034-2. ISBN   978-0-323-47912-7. S2CID   56977185.
  49. 1 2 3 Barry JA, Azizia MM, Hardiman PJ (1 September 2014). "Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis". Human Reproduction Update. 20 (5): 748–758. doi:10.1093/humupd/dmu012. PMC   4326303 . PMID   24688118.
  50. ↑ New MI (May 1993). "Nonclassical congenital adrenal hyperplasia and the polycystic ovarian syndrome". Annals of the New York Academy of Sciences. 687 (1): 193–205. Bibcode:1993NYASA.687..193N. doi:10.1111/j.1749-6632.1993.tb43866.x. PMID   8323173. S2CID   30161989.
  51. ↑ Hardiman P, Pillay OC, Atiomo W (May 2003). "Polycystic ovary syndrome and endometrial carcinoma". Lancet. 361 (9371): 1810–1812. doi:10.1016/S0140-6736(03)13409-5. PMID   12781553. S2CID   27453081.
  52. ↑ Mather KJ, Kwan F, Corenblum B (January 2000). "Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity". Fertility and Sterility. 73 (1): 150–156. doi: 10.1016/S0015-0282(99)00468-9 . PMID   10632431.
  53. ↑ Moran LJ, Misso ML, Wild RA, Norman RJ (2010). "Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis". Human Reproduction Update. 16 (4): 347–363. doi: 10.1093/humupd/dmq001 . PMID   20159883.
  54. ↑ Falcone T, Hurd RW (2007). Clinical Reproductive Medicine and Surgery. Elsevier Health Sciences. p. 223. ISBN   978-0-323-03309-1.
  55. ↑ "Polycystic ovary syndrome (PCOS) - Symptoms and causes". Mayo Clinic.
  56. ↑ Barry JA, Kuczmierczyk AR, Hardiman PJ (September 2011). "Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis". Human Reproduction. 26 (9): 2442–2451. doi: 10.1093/humrep/der197 . PMID   21725075.
  57. ↑ Ovalle F, Azziz R (June 2002). "Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus". Fertility and Sterility. 77 (6): 1095–1105. doi: 10.1016/s0015-0282(02)03111-4 . PMID   12057712.
  58. ↑ de Groot PC, Dekkers OM, Romijn JA, Dieben SW, Helmerhorst FM (1 July 2011). "PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis". Human Reproduction Update. 17 (4): 495–500. doi: 10.1093/humupd/dmr001 . PMID   21335359.
  59. ↑ Goldenberg N, Glueck C (February 2008). "Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation". Minerva Ginecologica. 60 (1): 63–75. PMID   18277353.
  60. ↑ Boomsma CM, Fauser BC, Macklon NS (January 2008). "Pregnancy complications in women with polycystic ovary syndrome". Seminars in Reproductive Medicine. 26 (1): 72–84. doi:10.1055/s-2007-992927. PMID   18181085. S2CID   260316768.
  61. ↑ "Iron Deficiency Injectables Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025". imarc. Retrieved 2023-08-02.
  62. 1 2 Page 836 (Section:Polycystic ovary syndrome) in: Fauser BC, Diedrich K, Bouchard P, Domínguez F, Matzuk M, Franks S, et al. (2011). "Contemporary genetic technologies and female reproduction". Human Reproduction Update. 17 (6): 829–847. doi:10.1093/humupd/dmr033. PMC   3191938 . PMID   21896560.
  63. 1 2 3 4 Legro RS, Strauss JF (September 2002). "Molecular progress in infertility: polycystic ovary syndrome". Fertility and Sterility. 78 (3): 569–576. doi: 10.1016/S0015-0282(02)03275-2 . PMID   12215335.
  64. ↑ Filippou P, Homburg R (July 2017). "Is foetal hyperexposure to androgens a cause of PCOS?". Human Reproduction Update. 23 (4): 421–432. doi: 10.1093/humupd/dmx013 . PMID   28531286.
  65. ↑ Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS (October 2015). "Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome". Endocrine Reviews (Review). 36 (5): 487–525. doi:10.1210/er.2015-1018. PMC   4591526 . PMID   26426951.
  66. 1 2 Crosignani PG, Nicolosi AE (2001). "Polycystic ovarian disease: heritability and heterogeneity". Human Reproduction Update. 7 (1): 3–7. doi: 10.1093/humupd/7.1.3 . PMID   11212071.
  67. 1 2 3 Strauss JF (November 2003). "Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome". Annals of the New York Academy of Sciences. 997 (1): 42–48. Bibcode:2003NYASA.997...42S. doi:10.1196/annals.1290.005. PMID   14644808. S2CID   23559461.
  68. 1 2 Hamosh A (12 September 2011). "POLYCYSTIC OVARY SYNDROME 1; PCOS1". OMIM . McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine. Archived from the original on 16 July 2015. Retrieved 15 November 2011.
  69. ↑ Amato P, Simpson JL (October 2004). "The genetics of polycystic ovary syndrome". Best Practice & Research. Clinical Obstetrics & Gynaecology. 18 (5): 707–718. doi:10.1016/j.bpobgyn.2004.05.002. PMID   15380142.
  70. ↑ Draper N, Walker EA, Bujalska IJ, Tomlinson JW, Chalder SM, Arlt W, et al. (August 2003). "Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency". Nature Genetics. 34 (4): 434–439. doi:10.1038/ng1214. PMID   12858176. S2CID   22772927.
  71. ↑ Ehrmann DA (March 2005). "Polycystic ovary syndrome". The New England Journal of Medicine. 352 (12): 1223–1236. doi:10.1056/NEJMra041536. PMID   15788499. S2CID   79796961.
  72. ↑ Faghfoori Z, Fazelian S, Shadnoush M, Goodarzi R (November 2017). "Nutritional management in women with polycystic ovary syndrome: A review study". Diabetes & Metabolic Syndrome (Review). 11 (Suppl 1): S429–S432. doi:10.1016/j.dsx.2017.03.030. PMID   28416368.
  73. ↑ Witchel SF, Oberfield SE, Peña AS (August 2019). "Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls". Journal of the Endocrine Society. 3 (8): 1545–1573. doi:10.1210/js.2019-00078. PMC   6676075 . PMID   31384717.
  74. ↑ Hoeger KM (May 2014). "Developmental origins and future fate in PCOS". Seminars in Reproductive Medicine. 32 (3): 157–158. doi:10.1055/s-0034-1371086. PMID   24715509. S2CID   32069697.
  75. ↑ Abbott DH, Barnett DK, Bruns CM, Dumesic DA (2005). "Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome?". Human Reproduction Update. 11 (4): 357–374. doi: 10.1093/humupd/dmi013 . PMID   15941725.
  76. ↑ Rasgon N (June 2004). "The relationship between polycystic ovary syndrome and antiepileptic drugs: a review of the evidence". Journal of Clinical Psychopharmacology. 24 (3): 322–334. doi:10.1097/01.jcp.0000125745.60149.c6. PMID   15118487. S2CID   24603227.
  77. ↑ Rutkowska A, Rachoń D (April 2014). "Bisphenol A (BPA) and its potential role in the pathogenesis of the polycystic ovary syndrome (PCOS)". Gynecological Endocrinology. 30 (4): 260–265. doi:10.3109/09513590.2013.871517. PMID   24397396. S2CID   5828672.
  78. 1 2 Palioura E, Diamanti-Kandarakis E (December 2013). "Industrial endocrine disruptors and polycystic ovary syndrome". Journal of Endocrinological Investigation. 36 (11): 1105–1111. doi:10.1007/bf03346762. PMID   24445124. S2CID   27141519.
  79. ↑ Hu X, Wang J, Dong W, Fang Q, Hu L, Liu C (November 2011). "A meta-analysis of polycystic ovary syndrome in women taking valproate for epilepsy". Epilepsy Research. 97 (1–2): 73–82. doi:10.1016/j.eplepsyres.2011.07.006. PMID   21820873. S2CID   26422134.
  80. ↑ "Endocrine Disruptors". National Institute of Environmental Health Sciences. Retrieved 2022-11-10.
  81. ↑ Merkin SS, Phy JL, Sites CK, Yang D (July 2016). "Environmental determinants of polycystic ovary syndrome". Fertility and Sterility. 106 (1): 16–24. doi: 10.1016/j.fertnstert.2016.05.011 . PMID   27240194.
  82. 1 2 3 4 Diamanti-Kandarakis E, Dunaif A (December 2012). "Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications". Endocrine Reviews. 33 (6): 981–1030. doi:10.1210/er.2011-1034. PMC   5393155 . PMID   23065822.
  83. ↑ Lewandowski KC, Cajdler-Łuba A, Salata I, Bieńkiewicz M, Lewiński A (2011). "The utility of the gonadotrophin releasing hormone (GnRH) test in the diagnosis of polycystic ovary syndrome (PCOS)". Endokrynologia Polska. 62 (2): 120–128. PMID   21528473. ProQuest   2464206947.
  84. ↑ Rojas J, Chávez M, Olivar L, Rojas M, Morillo J, Mejías J, Calvo M, Bermúdez V (2014). "Polycystic ovary syndrome, insulin resistance, and obesity: navigating the pathophysiologic labyrinth". Int J Reprod Med. 2014: 71905. doi: 10.1155/2014/719050 . PMC   4334071 . PMID   25763405.
  85. ↑ Ali HI, Elsadawy ME, Khater NH (March 2016). "Ultrasound assessment of polycystic ovaries: Ovarian volume and morphology; which is more accurate in making the diagnosis?!". The Egyptian Journal of Radiology and Nuclear Medicine. 47 (1): 347–350. doi: 10.1016/j.ejrnm.2015.10.002 .
  86. ↑ Sathyapalan T, Atkin SL (2010). "Mediators of inflammation in polycystic ovary syndrome in relation to adiposity". Mediators of Inflammation. 2010: 758656. doi: 10.1155/2010/758656 . PMC   2852606 . PMID   20396393.
  87. ↑ Fukuoka M, Yasuda K, Fujiwara H, Kanzaki H, Mori T (November 1992). "Interactions between interferon gamma, tumour necrosis factor alpha, and interleukin-1 in modulating progesterone and oestradiol production by human luteinized granulosa cells in culture". Human Reproduction. 7 (10): 1361–1364. doi:10.1093/oxfordjournals.humrep.a137574. PMID   1291559.
  88. ↑ González F, Rote NS, Minium J, Kirwan JP (January 2006). "Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome". The Journal of Clinical Endocrinology and Metabolism. 91 (1): 336–340. doi: 10.1210/jc.2005-1696 . PMID   16249279.
  89. ↑ Murri M, Luque-Ramírez M, Insenser M, Ojeda-Ojeda M, Escobar-Morreale HF (2013). "Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS): a systematic review and meta-analysis". Human Reproduction Update. 19 (3): 268–288. doi: 10.1093/humupd/dms059 . PMID   23303572.
  90. 1 2 3 4 Imaging in Polycystic Ovary Disease at eMedicine
  91. ↑ Lujan ME, Chizen DR, Pierson RA (August 2008). "Diagnostic criteria for polycystic ovary syndrome: pitfalls and controversies". Journal of Obstetrics and Gynaecology Canada. 30 (8): 671–679. doi:10.1016/S1701-2163(16)32915-2. PMC   2893212 . PMID   18786289.
  92. 1 2 3 4 5 6 Polycystic Ovarian Syndrome~workup at eMedicine
  93. ↑ Pedersen SD, Brar S, Faris P, Corenblum B (June 2007). "Polycystic ovary syndrome: validated questionnaire for use in diagnosis". Canadian Family Physician. 53 (6): 1042–7, 1041. PMC   1949220 . PMID   17872783.
  94. 1 2 Dewailly D, Lujan ME, Carmina E, Cedars MI, Laven J, Norman RJ, Escobar-Morreale HF (2013). "Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society". Human Reproduction Update. 20 (3): 334–352. doi: 10.1093/humupd/dmt061 . PMID   24345633.
  95. ↑ O'Brien WT (1 January 2011). Top 3 Differentials in Radiology. Thieme. p. 369. ISBN   978-1-60406-228-1. Archived from the original on 19 April 2016. Retrieved 30 August 2014. Ultrasound findings in PCOS include enlarged ovaries with peripheral follicles in a "string of pearls" configuration.
  96. ↑ Bordewijk EM, Ng KY, Rakic L, Mol BW, Brown J, Crawford TJ, van Wely M (February 2020). "Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome". The Cochrane Database of Systematic Reviews. 2 (2): CD001122. doi:10.1002/14651858.CD001122.pub5. PMC   7013239 . PMID   32048270.
  97. ↑ Somani N, Harrison S, Bergfeld WF (2008). "The clinical evaluation of hirsutism". Dermatologic Therapy. 21 (5): 376–391. doi:10.1111/j.1529-8019.2008.00219.x. PMID   18844715. S2CID   34029116.
  98. ↑ Sharquie KE, Al-Bayatti AA, Al-Ajeel AI, Al-Bahar AJ, Al-Nuaimy AA (July 2007). "Free testosterone, luteinizing hormone/follicle stimulating hormone ratio and pelvic sonography in relation to skin manifestations in patients with polycystic ovary syndrome". Saudi Medical Journal. 28 (7): 1039–1043. OCLC   151296412. PMID   17603706. INIST   18933286.
  99. 1 2 Banaszewska B, Spaczyński RZ, Pelesz M, Pawelczyk L (2003). "Incidence of elevated LH/FSH ratio in polycystic ovary syndrome women with normo- and hyperinsulinemia". Roczniki Akademii Medycznej W Bialymstoku. 48: 131–134. CiteSeerX   10.1.1.410.676 . PMID   14737959.
  100. ↑ Macpherson G (2002). Black's Medical Dictionary (40 ed.). Lanham, MD: Scarecrow Press. p. 496. ISBN   0-8108-4984-4.
  101. ↑ Dumont A, Robin G, Catteau-Jonard S, Dewailly D (December 2015). "Role of Anti-Müllerian Hormone in pathophysiology, diagnosis and treatment of Polycystic Ovary Syndrome: a review". Reproductive Biology and Endocrinology (Review). 13: 137. doi: 10.1186/s12958-015-0134-9 . PMC   4687350 . PMID   26691645.
  102. ↑ Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, et al. (2014). "The physiology and clinical utility of anti-Mullerian hormone in women". Human Reproduction Update (Review). 20 (3): 370–385. doi: 10.1093/humupd/dmt062 . hdl: 10023/7488 . PMID   24430863.
  103. ↑ Broer SL, Broekmans FJ, Laven JS, Fauser BC (2014). "Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications". Human Reproduction Update. 20 (5): 688–701. doi: 10.1093/humupd/dmu020 . PMID   24821925.
  104. ↑ Andersen M, Glintborg D (September 2018). "Diagnosis and follow-up of type 2 diabetes in women with PCOS: a role for OGTT?". European Journal of Endocrinology. 179 (3): D1–D14. doi: 10.1530/EJE-18-0237 . PMID   29921567. S2CID   49315075.
  105. ↑ Muniyappa R, Madan R, Varghese RT (2000). "Assessing Insulin Sensitivity and Resistance in Humans". In Feingold KR, Anawalt B, Boyce A, Chrousos G (eds.). Endotext. South Dartmouth (MA): MDText.com, Inc. PMID   25905189 . Retrieved 2022-10-19.
  106. 1 2 3 Polycystic Ovary Syndrome. 2022. doi:10.1016/c2018-0-03276-4. ISBN   978-0-12-823045-9. S2CID   222263507.
  107. 1 2 National Institutes of Health (NIH) (2014-07-14). "Treatments for Infertility Resulting from PCOS". Archived from the original on 2 April 2015. Retrieved 13 March 2015.
  108. 1 2 Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (December 2013). "Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline". The Journal of Clinical Endocrinology and Metabolism. 98 (12): 4565–4592. doi:10.1210/jc.2013-2350. PMC   5399492 . PMID   24151290.
  109. ↑ Magkos F, Yannakoulia M, Chan JL, Mantzoros CS (2009). "Management of the metabolic syndrome and type 2 diabetes through lifestyle modification". Annual Review of Nutrition. 29: 223–256. doi:10.1146/annurev-nutr-080508-141200. PMC   5653262 . PMID   19400751.
  110. ↑ Veltman-Verhulst SM, Boivin J, Eijkemans MJ, Fauser BJ (2012). "Emotional distress is a common risk in women with polycystic ovary syndrome: a systematic review and meta-analysis of 28 studies". Human Reproduction Update. 18 (6): 638–651. doi: 10.1093/humupd/dms029 . PMID   22824735.
  111. ↑ Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. (Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines) (July 2016). "American association of clinical endocrinologists and American college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity". Endocrine Practice. 22 (Suppl 3): 1–203. doi: 10.4158/EP161365.GL . PMID   27219496.
  112. 1 2 Moran LJ, Ko H, Misso M, Marsh K, Noakes M, Talbot M, et al. (2013). "Dietary composition in the treatment of polycystic ovary syndrome: a systematic review to inform evidence-based guidelines". Human Reproduction Update. 19 (5): 432. doi: 10.1093/humupd/dmt015 . PMID   23727939.
  113. 1 2 3 4 5 6 7 8 9 10 11 Polycystic Ovarian Syndrome~treatment at eMedicine
  114. ↑ Krul-Poel YH, Snackey C, Louwers Y, Lips P, Lambalk CB, Laven JS, Simsek S (December 2013). "The role of vitamin D in metabolic disturbances in polycystic ovary syndrome: a systematic review". European Journal of Endocrinology (Review). 169 (6): 853–865. doi: 10.1530/EJE-13-0617 . PMID   24044903.
  115. ↑ He C, Lin Z, Robb SW, Ezeamama AE (2015). "Serum Vitamin D Levels and Polycystic Ovary syndrome: A Systematic Review and Meta-Analysis". Nutrients. 7 (6): 4555–4577. doi: 10.3390/nu7064555 . PMC   4488802 . PMID   26061015.
  116. ↑ Huang G, Coviello A (December 2012). "Clinical update on screening, diagnosis and management of metabolic disorders and cardiovascular risk factors associated with polycystic ovary syndrome". Current Opinion in Endocrinology, Diabetes and Obesity. 19 (6): 512–519. doi:10.1097/med.0b013e32835a000e. PMID   23108199. S2CID   205792902.
  117. ↑ Alesi S, Forslund M, Melin J, Romualdi D, Peña A, Tay CT, et al. (September 2023). "Efficacy and safety of anti-androgens in the management of polycystic ovary syndrome: a systematic review and meta-analysis of randomised controlled trials". eClinicalMedicine. 63: 102162. doi:10.1016/j.eclinm.2023.102162. PMC   10424142 . PMID   37583655.
  118. ↑ Lord JM, Flight IH, Norman RJ (October 2003). "Metformin in polycystic ovary syndrome: systematic review and meta-analysis". BMJ. 327 (7421): 951–953. doi:10.1136/bmj.327.7421.951. PMC   259161 . PMID   14576245.
  119. ↑ Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B, et al. (March 2011). "Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis". Clinical Endocrinology. 74 (3): 332–339. doi:10.1111/j.1365-2265.2010.03917.x. PMID   21050251. S2CID   19620846.
  120. ↑ Grover A, Yialamas MA (March 2011). "Metformin or thiazolidinedione therapy in PCOS?". Nature Reviews. Endocrinology. 7 (3): 128–129. doi:10.1038/nrendo.2011.16. PMID   21283123. S2CID   26162421. Gale   A250471047.
  121. ↑ National Institute for Health and Clinical Excellence . 11 Clinical guideline 11 : Fertility: assessment and treatment for people with fertility problems . London, 2004.
  122. ↑ Balen A (December 2008). "Metformin therapy for the management of infertility in women with polycystic ovary syndrome" (PDF). Scientific Advisory Committee Opinion Paper 13. Royal College of Obstetricians and Gynaecologists. Archived from the original (PDF) on 2009-12-18. Retrieved 2009-12-13.
  123. ↑ Leeman L, Acharya U (August 2009). "The use of metformin in the management of polycystic ovary syndrome and associated anovulatory infertility: the current evidence". Journal of Obstetrics and Gynaecology. 29 (6): 467–472. doi:10.1080/01443610902829414. PMID   19697191. S2CID   3339588.
  124. ↑ NICE (December 2018). "Metformin Hydrochloride". National Institute for Care Excellence. NICE. Retrieved 2017-11-02.
  125. ↑ Feig DS, Moses RG (October 2011). "Metformin therapy during pregnancy: good for the goose and good for the gosling too?". Diabetes Care. 34 (10): 2329–2330. doi:10.2337/dc11-1153. PMC   3177745 . PMID   21949224.
  126. ↑ Cassina M, Donà M, Di Gianantonio E, Litta P, Clementi M (1 September 2014). "First-trimester exposure to metformin and risk of birth defects: a systematic review and meta-analysis". Human Reproduction Update. 20 (5): 656–669. doi: 10.1093/humupd/dmu022 . PMID   24861556.
  127. ↑ Wang FF, Wu Y, Zhu YH, Ding T, Batterham RL, Qu F, Hardiman PJ (October 2018). "Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis" (PDF). Obesity Reviews. 19 (10): 1424–1445. doi:10.1111/obr.12720. PMID   30066361. S2CID   51891552.
  128. ↑ Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH (December 2019). "Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome". The Cochrane Database of Systematic Reviews. 2019 (12): CD013505. doi:10.1002/14651858.CD013505. PMC   6915832 . PMID   31845767.
  129. ↑ "Erase the Dread and Stigma of PCOD". Matria. Retrieved 2022-01-19.
  130. ↑ Balen AH, Morley LC, Misso M, Franks S, Legro RS, Wijeyaratne CN, et al. (November 2016). "The management of anovulatory infertility in women with polycystic ovary syndrome: an analysis of the evidence to support the development of global WHO guidance". Human Reproduction Update. 22 (6): 687–708. doi:10.1093/humupd/dmw025. PMID   27511809.
  131. ↑ Qiao J, Feng HL (2010). "Extra- and intra-ovarian factors in polycystic ovary syndrome: impact on oocyte maturation and embryo developmental competence". Human Reproduction Update. 17 (1): 17–33. doi:10.1093/humupd/dmq032. PMC   3001338 . PMID   20639519.
  132. ↑ "What are some causes of female infertility?". National Institute of Child Health and Human Development, National Institutes of Health. 31 January 2017.
  133. ↑ Jurczewska J, Szostak-Węgierek D (April 2022). "The Influence of Diet on Ovulation Disorders in Women-A Narrative Review". Nutrients. 14 (8): 1556. doi: 10.3390/nu14081556 . PMC   9029579 . PMID   35458118.
  134. ↑ Wang L, Liu Y, Tan H, Huang S (May 2022). "Transtheoretical model-based mobile health application for PCOS". Reproductive Health. 19 (1): 117. doi: 10.1186/s12978-022-01422-w . PMC   9097413 . PMID   35549736.
  135. ↑ Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C (September 2022). "Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome". The Cochrane Database of Systematic Reviews. 2022 (9): CD010287. doi:10.1002/14651858.CD010287.pub4. PMC   9514207 . PMID   36165742.
  136. ↑ Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P (October 2018). "Ovulation induction in polycystic ovary syndrome". Acta Obstetricia et Gynecologica Scandinavica. 97 (10): 1162–1167. doi: 10.1111/aogs.13395 . hdl: 10852/72989 . PMID   29889977.
  137. ↑ Hu S, Yu Q, Wang Y, Wang M, Xia W, Zhu C (May 2018). "Letrozole versus clomiphene citrate in polycystic ovary syndrome: a meta-analysis of randomized controlled trials". Archives of Gynecology and Obstetrics. 297 (5): 1081–1088. doi:10.1007/s00404-018-4688-6. PMID   29392438. S2CID   4800270.
  138. ↑ Penzias A, Bendikson K, Butts S, Coutifaris C, Falcone T, Fossum G, Gitlin S, Gracia C, Hansen K, La Barbera A, Mersereau J, Odem R, Paulson R, Pfeifer S, Pisarska M, Rebar R, Reindollar R, Rosen M, Sandlow J, Vernon M (September 2017). "Role of metformin for ovulation induction in infertile patients with polycystic ovary syndrome (PCOS): a guideline". Fertility and Sterility. 108 (3): 426–441. doi: 10.1016/j.fertnstert.2017.06.026 . PMID   28865539.
  139. ↑ Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, et al. (February 2007). "Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome". The New England Journal of Medicine. 356 (6): 551–566. doi: 10.1056/NEJMoa063971 . PMID   17287476.[ non-primary source needed ]
  140. ↑ Homburg R (October 2004). "Management of infertility and prevention of ovarian hyperstimulation in women with polycystic ovary syndrome". Best Practice & Research. Clinical Obstetrics & Gynaecology. 18 (5): 773–788. doi:10.1016/j.bpobgyn.2004.05.006. PMID   15380146.
  141. ↑ Ghanem ME, Elboghdady LA, Hassan M, Helal AS, Gibreel A, Houssen M, et al. (November 2013). "Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial". Journal of Assisted Reproduction and Genetics. 30 (11): 1477–1485. doi:10.1007/s10815-013-0090-2. PMC   3879942 . PMID   24014214.
  142. ↑ Zhuang J, Wang X, Xu L, Wu T, Kang D (May 2013). "Antidepressants for polycystic ovary syndrome". The Cochrane Database of Systematic Reviews. 2013 (5): CD008575. doi:10.1002/14651858.CD008575.pub2. PMC   7390273 . PMID   23728677.
  143. ↑ Diamanti-Kandarakis E, Christakou C, Palioura E, Kandaraki E, Livadas S (June 2008). "Does polycystic ovary syndrome start in childhood?". Pediatric Endocrinology Reviews. 5 (4): 904–911. PMID   18552753.
  144. ↑ Fraison E, Kostova E, Moran LJ, Bilal S, Ee CC, Venetis C, Costello MF (August 2020). "Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome". The Cochrane Database of Systematic Reviews. 2020 (8): CD005552. doi:10.1002/14651858.CD005552.pub3. PMC   7437400 . PMID   32794179.
  145. ↑ "Polycystic ovary syndrome – Treatment". United Kingdom: National Health Service. 17 October 2011. Archived from the original on 6 November 2011. Retrieved 19 November 2011.
  146. 1 2 Polycystic Ovarian Syndrome~medication at eMedicine
  147. ↑ van Zuuren EJ, Fedorowicz Z, Carter B, Pandis N (April 2015). "Interventions for hirsutism (excluding laser and photoepilation therapy alone)". The Cochrane Database of Systematic Reviews. 2015 (4): CD010334. doi:10.1002/14651858.CD010334.pub2. PMC   6481758 . PMID   25918921.
  148. ↑ "Irregular periods - NHS". Nhs.uk. 2020-10-21. Retrieved 2022-07-19.
  149. ↑ "What are the health risks of PCOS?". Verity – PCOS Charity. Verity. 2011. Archived from the original on 25 December 2012. Retrieved 21 November 2011.
  150. ↑ Pundir J, Psaroudakis D, Savnur P, Bhide P, Sabatini L, Teede H, et al. (February 2018). "Inositol treatment of anovulation in women with polycystic ovary syndrome: a meta-analysis of randomised trials" (PDF). BJOG. 125 (3): 299–308. doi:10.1111/1471-0528.14754. PMID   28544572. S2CID   21090113.
  151. ↑ Amoah-Arko A, Evans M, Rees A (20 October 2017). "Effects of myoinositol and D-chiro inositol on hyperandrogenism and ovulation in women with polycystic ovary syndrome: a systematic review". Endocrine Abstracts. doi:10.1530/endoabs.50.P363.
  152. ↑ Unfer V, Carlomagno G, Dante G, Facchinetti F (July 2012). "Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials". Gynecological Endocrinology. 28 (7): 509–515. doi:10.3109/09513590.2011.650660. PMID   22296306. S2CID   24582338.
  153. ↑ Zeng L, Yang K (January 2018). "Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis". Endocrine. 59 (1): 30–38. doi:10.1007/s12020-017-1442-y. PMID   29052180. S2CID   4376339.
  154. ↑ Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D'Anna R (October 2018). "Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials". Archives of Gynecology and Obstetrics. 298 (4): 675–684. doi:10.1007/s00404-018-4861-y. PMID   30078122. S2CID   51921158.
  155. ↑ Galazis N, Galazi M, Atiomo W (April 2011). "D-Chiro-inositol and its significance in polycystic ovary syndrome: a systematic review". Gynecological Endocrinology. 27 (4): 256–262. doi:10.3109/09513590.2010.538099. PMID   21142777. S2CID   1989262.
  156. ↑ Lim CE, Ng RW, Cheng NC, Zhang GS, Chen H (July 2019). "Acupuncture for polycystic ovarian syndrome". The Cochrane Database of Systematic Reviews. 2019 (7): CD007689. doi:10.1002/14651858.CD007689.pub4. PMC   6603768 . PMID   31264709.
  157. ↑ Wu XK, Stener-Victorin E, Kuang HY, Ma HL, Gao JS, Xie LZ, et al. (June 2017). "Effect of Acupuncture and Clomiphene in Chinese Women With Polycystic Ovary Syndrome: A Randomized Clinical Trial". JAMA. 317 (24): 2502–2514. doi:10.1001/jama.2017.7217. PMC   5815063 . PMID   28655015.
  158. 1 2 3 Kovacs GT, Norman R (2007-02-22). Polycystic Ovary Syndrome. Cambridge University Press. p. 4. ISBN   978-1-139-46203-7. Archived from the original on 16 June 2013. Retrieved 29 March 2013.
  159. ↑ Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–2196. doi:10.1016/S0140-6736(12)61729-2. PMC   6350784 . PMID   23245607.
  160. ↑ McLuskie I, Newth A (January 2017). "New diagnosis of polycystic ovary syndrome". BMJ. 356: i6456. doi:10.1136/bmj.i6456. hdl: 10044/1/44217 . PMID   28082338. S2CID   13042313.
  161. ↑ Pruthi B (26 September 2019). "One in five Indian women suffers from PCOS". The Hindu. Retrieved April 16, 2021.
  162. ↑ Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, et al. (July 2011). "Racial influence on the polycystic ovary syndrome phenotype: a black and white case-control study". Fertility and Sterility. 96 (1): 224–229.e2. doi:10.1016/j.fertnstert.2011.05.002. PMC   3132396 . PMID   21723443.
  163. ↑ Hillman JK, Johnson LN, Limaye M, Feldman RA, Sammel M, Dokras A (September 2013). "Black women with polycystic ovary syndrome (PCOS) have increased risk for metabolic syndrome (MET SYN) and cardiovascular disease (CVD) compared to white women with PCOS". Fertility and Sterility. 100 (3): S100–S101. doi: 10.1016/j.fertnstert.2013.07.1707 .
  164. ↑ Elghobashy M, Lau GM, Davitadze M, Gillett CD, O'Reilly MW, Arlt W, et al. (2023). "Concerns and expectations in women with polycystic ovary syndrome vary across age and ethnicity: findings from PCOS Pearls Study". Frontiers in Endocrinology. 14: 1175548. doi: 10.3389/fendo.2023.1175548 . PMC   10446892 . PMID   37621648.
  165. ↑ "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome (2023)". www.asrm.org. Retrieved 2023-11-26.
  166. ↑ Polson DW, Adams J, Wadsworth J, Franks S (April 1988). "Polycystic ovaries--a common finding in normal women". Lancet. 1 (8590): 870–872. doi:10.1016/s0140-6736(88)91612-1. PMID   2895373. S2CID   41297081.
  167. 1 2 Clayton RN, Ogden V, Hodgkinson J, Worswick L, Rodin DA, Dyer S, Meade TW (August 1992). "How common are polycystic ovaries in normal women and what is their significance for the fertility of the population?". Clinical Endocrinology. 37 (2): 127–134. doi:10.1111/j.1365-2265.1992.tb02296.x. PMID   1395063. S2CID   12384062.
  168. ↑ Farquhar CM, Birdsall M, Manning P, Mitchell JM, France JT (February 1994). "The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women". The Australian & New Zealand Journal of Obstetrics & Gynaecology. 34 (1): 67–72. doi:10.1111/j.1479-828X.1994.tb01041.x. PMID   8053879. S2CID   312422.
  169. ↑ van Santbrink EJ, Hop WC, Fauser BC (March 1997). "Classification of normogonadotropic infertility: polycystic ovaries diagnosed by ultrasound versus endocrine characteristics of polycystic ovary syndrome". Fertility and Sterility. 67 (3): 452–458. doi: 10.1016/S0015-0282(97)80068-4 . PMID   9091329.
  170. ↑ Hardeman J, Weiss BD (March 2014). "Intrauterine devices: an update". American Family Physician. 89 (6): 445–450. PMID   24695563.
  171. ↑ Chahal N, Quinn M, Jaswa EA, Kao CN, Cedars MI, Huddleston HG (December 2020). "Comparison of metabolic syndrome elements in White and Asian women with polycystic ovary syndrome: results of a regional, American cross-sectional study". F&S Reports. 1 (3): 305–313. doi:10.1016/j.xfre.2020.09.008. PMC   8244318 . PMID   34223261.
  172. ↑ Azziz R, Marin C, Hoq L, Badamgarav E, Song P (August 2005). "Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span". The Journal of Clinical Endocrinology and Metabolism. 90 (8): 4650–4658. doi: 10.1210/jc.2005-0628 . PMID   15944216.
  173. ↑ "RCDC Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)". NIH. Archived from the original on 28 February 2019. Retrieved 3 December 2018.
  174. 1 2 Chaudhari AP, Mazumdar K, Mehta PD (2018). "Anxiety, Depression, and Quality of Life in Women with Polycystic Ovarian Syndrome". Indian Journal of Psychological Medicine. 40 (3): 239–246. doi: 10.4103/IJPSYM.IJPSYM_561_17 . PMC   5968645 . PMID   29875531.
  175. ↑ "Sarah Hall investigates polycystic ovary syndrome". The Guardian. 2002-02-28. Retrieved 2022-01-21.
  176. ↑ Migdol E. "'Teen Mom' Star Nails the 'Lose-Lose' Side of Chronic Illness Doctors Don't Always Get". The Mighty. Retrieved 2022-11-14.
  177. ↑ "All the celebrities who've opened up about life with Polycystic Ovary Syndrome". Cosmopolitan. 26 November 2021. Retrieved 2022-09-01.
  178. ↑ Chowdhury J. "What Every Woman Should Know About PCOS". www.refinery29.com. Retrieved 2022-01-21.
  179. ↑ "Actress Jaime King on her investment in Allara, a chronic care platform for women". Fortune. Retrieved 2022-09-01.
  180. ↑ "Chrisette Michele Opens Up About Living With PCOS & No Longer Being Vegan - BlackDoctor.org - Where Wellness & Culture Connect". BlackDoctor.org. 2015-12-10. Retrieved 2022-01-22.
  181. ↑ "Lea Michele On How PCOS Changed Her Relationship With Food: 'The Side Effects Can Be Brutal'". Health Magazine. Archived from the original on 2022-09-01. Retrieved 2022-09-01.
  182. ↑ Natale N (2021-11-17). "Keke Palmer Says PCOS Causes Facial Hair and Adult Acne". Prevention. Retrieved 2022-01-21.
  183. ↑ Seemayer Z (September 26, 2017). "Sasha Pieterse Tears Up Over Health Problems, Opens Up About Losing 15 Pounds Since Joining 'DWTS'". Entertainment Tonight. Retrieved September 27, 2017.
  184. ↑ Mizoguchi K, Stern AB (October 5, 2017). "Sasha Pieterse Wows on People's Ones to Watch Red Carpet as She Reveals Why She's 'So Thankful to DWTS'". people.com. Retrieved 2021-12-11.
  185. ↑ "'Star Wars: The Force Awakens' Actress Opens Up About Painful Disorder". ABC News. Retrieved 2022-01-21.
  186. ↑ "Romee Strijd's Pregnancy Announcement Comes With an Honest Message About Reproductive Health". Vogue. 29 May 2020. Retrieved 2022-09-01.
  187. ↑ Silman A (March 10, 2020). "Lee's American Dream". The Cut . New York Media . Retrieved April 12, 2023.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.